ALK and non-small cell lung carcinoma: A small phase II trial is ongoing, assessing the efficacy of six weeks of neoadjuvant crizotinib in patients with MET, ROS1, or ALK alterations and resectable stage IA-IIIA NSCLC (NCT03088930).